Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 1016-1026

  Ionin, Boris ^a   Hopkins, Robert J ^a   Pleune, Brett ^a   Sivko, Gloria S ^b   Reid, Frances M ^b   Clement, Kristin H ^b   Rudge, Thomas L ^b   Stark, Gregory V ^b   Innes, Alison ^a   Sari, Suha ^a   Guina, Tina ^a   Howard, Cris ^a   Smith, Jeffrey ^a   Swoboda, M Lisa ^a   Vert Wong, Ekaterina ^a   Johnson, Virginia ^a   Nabors, Gary S ^a   Skiadopoulos, Mario H ^a  

^a Emergent Biosolutions   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; LEVOFLOXACIN; NEUTRALIZING ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABBIT; SURVIVAL PREDICTION; SURVIVAL RATE;

EID: 84880462374     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00099-13     Document Type: Article

References (43)

1. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252. (Erratum, 288:1849.)
2. Brossier F, Mock M. 2010. Toxins of Bacillus anthracis. Toxicon 39:1747-1755.
3. Bann JG, Hultgren SJ. 2004. Structural biology: anthrax hijacks host receptor. Nature 430:843-844. (Pubitemid 39119203)
4. Kintzer AF, Sterling HJ, Tang II, Williams ER, Krantz BA. 2010. Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism. PLoS One 5:e13888. doi:10.1371/journal.pone.0013888.
5. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773. (Pubitemid 32800762)
6. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A, Velan B. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893. (Pubitemid 32332179)
7. Beedham RJ, Turnbull PC, Williamson ED. 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19:4409-4416. (Pubitemid 32718664)
8. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430. (Pubitemid 37510273)
9. Little SF, Ivins BE, Webster WM, Fellows PF, Pitt MLM, Norris SLW, Andrews GP. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24:2530-2536. (Pubitemid 43290383)
10. Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO. 2012. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci. Transl. Med. 4:151ra126. doi:10.1126/scitranslmed.3004073.
11. Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. (Lond.) 54:28-36.
12. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, Lawrence WB. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1243. (Pubitemid 23115626)
13. Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542. (Pubitemid 44684862)
14. Novartis Vaccines and Diagnostics. 2012. RabAvert rabies vaccine package insert. Novartis Vaccines and Diagnostics, Inc. Cambridge, MA. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM312931.pdf.
15. Sanofi Pasteur. 2012. Imovax rabies vaccine package insert. Sanofi Pasteur, Inc. Swiftwater, PA. http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM133484.pdf.
16. GlaxoSmithKline. 2012. ENGERIX-B hepatitis B vaccine (recombinant) package insert. GlaxoSmithKline, Rixensart, Belgium. http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf.
17. Merck & Co. 2011. RECOMBIVAX HB® hepatitis B vaccine (recombinant) package insert. Merck & Co., Inc., Whitehouse Station, NJ. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM110114.pdf.
18. Aventis Pasteur. 2005. Tetanus toxoid adsorbed package insert. Aventis Pasteur, Swiftwater, PA. http://www.fda.gov/downloads/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UCM142732.pdf.
19. Emergent BioSolutions. 2012. BioThrax (anthrax vaccine adsorbed) package insert. Emergent BioDefense Operations Lansing LLC, Lansing, MI. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/UCM074923.pdf.
20. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health Nations Health 52:632-645.
21. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL (ed). 2002. The anthrax vaccine: is it safe? Does it work? National Academy Press, Washington, DC.
22. Code of Federal Regulations. 2012. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use. 21 CFR 601.25. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=601.25.
23. Code of Federal Regulations. 2012. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. 21 CFR 601.41. http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=601.41.
24. FDA. 2007. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. U.S. Department of Health and Human Services. Food and Drug Administration. http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm091990.pdf.
25. Vaccines and Related Biological Products Advisory Committee. 17 May 2007. Transcript of Vaccines and Related Biological Products Advisory Committee Meeting. U.S. Department of Health and Human Services, Food and Drug Administration. Gaithersburg, MD. http://www.fda.gov/ohrms/dockets/ac/07/ transcripts/2007-4292t2.pdf.
26. Vaccines and Related Biological Products Advisory Committee. 6-7 April 2011. Vaccines and Related Biological Products Advisory Committee meeting summary minutes. U.S. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm254361.htm.
27. Burns DL. 2012. Licensure of vaccines using the Animal Rule. Curr. Opin. Virol. 2:353-356.
28. CDER and CBER. 2009. Guidance for industry animal models: essential elements to address efficacy under the Animal Rule. U.S. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf.
29. CBER. 8 November 2007. Anthrax vaccines: bridging correlates of protection in animals to immunogenicity in humans. U.S. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/ BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ TranscriptsMinutes/UCM054424.pdf.
30. Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM. 2009.Ashort course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J. Infect. Dis. 199:336-341.
31. CBER. 23 April 2002. Anthrax vaccines: efficacy testing and surrogate markers of immunity. U.S. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/ WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054606.pdf.
32. Leffel EK, Bourdage JS, Williamson ED, Duchars M, Fuerst TR, Fusco PC. 2012. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Clin. Vaccine Immunol. 19:1158-1164.
33. Vaccines and Related Biological Products Advisory Committee. 16 November 2010. Transcript of FDA Advisory Committee Meeting. Vaccines and Related Biological Products Advisory Committee Meeting Materials. U.S. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm237045.htm.
34. Brachman PS, Friedlander AM, Grabenstein JD. 2008. Anthrax vaccine, p 111-126. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 5th ed. Saunders, Philadelphia, PA.
35. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992. (Pubitemid 28521045)
36. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83(8):1201-1209. (Pubitemid 37013055)
37. Li H, Soroka SD, Taylor TH, Jr., Stamey KL, Stinson KW, Freeman AE, Abramson DR, Desai R, Cronin LX, Oxford JW, Caba J, Pleatman C, Pathak S, Schmidt DS, Semenova VA, Martin SK, Wilkins PP, Quinn CP. 2008. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J. Immunol. Methods 333:89-106.
38. Omland KS, Brys A, Lansky D, Clement K, Lynn F, the Participating Laboratories. 2008. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin. Vaccine Immunol. 15:946-953. (Pubitemid 351966996)
39. Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Stamey K, Steward-Clark E, Schmidt DS, Mothershed E, Pruckler J, Schwartz S, Benson RF, Helsel LO, Holder PF, Johnson SE, Kellum M, Messmer T, Thacker WL, Besser L, Plikaytis BD, Taylor TH, Jr, Freeman AE, Wallace KJ, Dull P, Sejvar J, Bruce E, Moreno R, Schuchat A, Lingappa JR, Martin SK, Walls J, Bronsdon M, Carlone GM, Bajani-Ari M, Ashford DA, Stephens DS, Perkins BA. 2002. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis. 10:1103-1110. (Pubitemid 35257002)
40. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N, AVRP Laboratory Working Group. 2012. A three-dose intramuscular schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol. 19:1730-1745.
41. Chakrabarti A, Hopkins R, Malkevich N, Ionin B, Skiadopoulos M, Smith J, Nabors G. 2009. Recent advances in the development of a human anthrax intravenous immune globulin (AIGIV) for treatment of inhalation anthrax disease, abstr. 119C. Bacillus-ACT 2009: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, Santa Fe, NM.
42. Basu S, Mytle N, Van Zandt KE, Meister GT, Ionin B, Chakrabarti AC, Nabors GS, Skiadopoulos MH. 2011. Postexposure efficacy of human anthrax immune globulin, intravenous (AIGIV) in rabbits, abstr. 119-Mo. Bacillus-ACT 2011: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, Bruges, Belgium.
43. Nuzum E. 16 November 2010. DMID/NIAID efforts that support the pathway to licensure for protective antigen-based anthrax vaccines for a post-exposure indication using the animal rule. Vaccines and Related Biological Products Advisory Committee Meeting Presentations (PPTX-895KB). http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm239733.htm. of Health and Human Services